Literature DB >> 19955951

French recommendations on the management of invasive cervical cancer during pregnancy.

Philippe Morice1, Febrice Narducci, Patrice Mathevet, Henri Marret, Emile Darai, Denis Querleu.   

Abstract

BACKGROUND: Cervical cancer is one of the most frequently diagnosed cancers during pregnancy, but the management of such cases remains unclear. A Working Group was set up in 2007 in France to propose national recommendations for the management of pregnant patients with invasive cervical carcinoma.
METHODS: The recommendations are based on this literature review conducted by the members of the Working Group.
RESULTS: Management of cervical cancer during pregnancy depends on 5 factors: stage of the disease (and the tumor size), nodal status, histological subtype of the tumor, term of the pregnancy, and whether the patient wishes to continue her pregnancy. In patients with early-stage disease diagnosed during the first 2 trimesters of pregnancy, there is an increasing tendency to preserve the pregnancy while awaiting fetal maturity in patients with absence of nodal involvement. The delivery (when the fetal maturity is attained) should be then performed using a cesarean section.
CONCLUSIONS: This article proposes recommendations for the management of pregnant patients with invasive cervical cancer. These recommendations have been validated by the 3 main scientific societies of gynecologic oncology, pelvic surgery, and obstetrics and gynecology in France.

Entities:  

Mesh:

Year:  2009        PMID: 19955951     DOI: 10.1111/IGC.0b013e3181a83017

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Malignancies associated with pregnancy: an analysis of 21 clinical cases.

Authors:  Y Liu; Y Liu; Y Wang; X Chen; H Chen; J Zhang
Journal:  Ir J Med Sci       Date:  2014-02-23       Impact factor: 1.568

2.  Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies.

Authors:  Sileny N Han; Mina Mhallem Gziri; Kristel Van Calsteren; Frédéric Amant
Journal:  Ther Adv Med Oncol       Date:  2013-07       Impact factor: 8.168

3.  Cervical Carcinoma in Early Pregnancy - Successful Birth by Caesarean Section Followed by Radical Hysterectomy.

Authors:  K Schreiber; S Rothe; M Untch
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

4.  Pregnancy-associated-cancer in the French West Indies (Martinique): maternal and neonatal outcomes.

Authors:  Kathleen Melan; Jean-Luc Volumenie; Gaël Wan-Ajouhu; Stephen Ulric-Gervaise; Jacqueline Veronique-Baudin; Clarisse Joachim
Journal:  BMC Pregnancy Childbirth       Date:  2017-10-02       Impact factor: 3.007

5.  The Safety and Effectiveness of Abdominal Radical Trachelectomy for Early-Stage Cervical Cancer During Pregnancy.

Authors:  Kosuke Yoshihara; Tatsuya Ishiguro; Makoto Chihara; Eiri Shima; Sosuke Adachi; Masanori Isobe; Kazufumi Haino; Masayuki Yamaguchi; Masayuki Sekine; Katsunori Kashima; Koichi Takakuwa; Nobumichi Nishikawa; Takayuki Enomoto
Journal:  Int J Gynecol Cancer       Date:  2018-05       Impact factor: 3.437

6.  Trends in Pregnancy-Associated Cervical Cancer in Japan between 2012 and 2017: A Multicenter Survey.

Authors:  Sayako Enomoto; Kosuke Yoshihara; Eiji Kondo; Akiko Iwata; Mamoru Tanaka; Tsutomu Tabata; Yoshiki Kudo; Eiji Kondoh; Masaki Mandai; Takashi Sugiyama; Aikou Okamoto; Tsuyoshi Saito; Takayuki Enomoto; Tomoaki Ikeda
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 7.  Guidelines for Cancer Treatment during Pregnancy: Ethics-Related Content Evolution and Implications for Clinicians.

Authors:  Alma Linkeviciute; Rita Canario; Fedro Alessandro Peccatori; Kris Dierickx
Journal:  Cancers (Basel)       Date:  2022-09-03       Impact factor: 6.575

Review 8.  Gynecologic Malignancies in Pregnancy: Balancing Fetal Risks With Oncologic Safety.

Authors:  Christina N Cordeiro; Mary L Gemignani
Journal:  Obstet Gynecol Surv       Date:  2017-03       Impact factor: 2.347

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.